MT1011

MT1011 is a novel synthetic peptide and small molecule developed as an anticoagulant reversal agent, specifically designed to reverse the effects of blood thinners—especially direct oral anticoagulants targeting factor IIa and Xa. Its primary therapeutic area is hemorrhage, addressing situations where prompt reversal of anticoagulation is necessary, such as in bleeding emergencies. Developed by Shaanxi Micot Technology, the agent has reached Phase 1 clinical trials focused on safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. The precise molecular mechanism of MT1011 is not fully disclosed, but its use as an anticoagulant reversal agent suggests it likely binds directly to or inactivates circulating anticoagulants including rivaroxaban and apixaban.